Drug Type Synthetic peptide |
Synonyms Astuprotimut-R, Astuprotimut-R (USAN), Astuprotimut-R(Ludwig Institute for Cancer Research) + [19] |
Target |
Mechanism MAGEA3 modulators(Melanoma-associated antigen 3 modulators), Immunostimulants |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhasePhase 3 |
First Approval Date- |
RegulationOrphan Drug (US) |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Melanoma | Phase 3 | - | - | |
Non-Small Cell Lung Cancer | Phase 2 | EE | 04 Oct 2007 | |
Non-Small Cell Lung Cancer | Phase 2 | CN | 04 Oct 2007 | |
Non-Small Cell Lung Cancer | Phase 2 | PL | 04 Oct 2007 | |
Non-Small Cell Lung Cancer | Phase 2 | ES | 04 Oct 2007 | |
Non-Small Cell Lung Cancer | Phase 2 | TH | 04 Oct 2007 | |
Non-Small Cell Lung Cancer | Phase 2 | NL | 04 Oct 2007 | |
Non-Small Cell Lung Cancer | Phase 2 | IN | 04 Oct 2007 | |
Non-Small Cell Lung Cancer | Phase 2 | CA | 04 Oct 2007 | |
Non-Small Cell Lung Cancer | Phase 2 | HK | 04 Oct 2007 |
Phase 2 | 44 | recMAGE-A3 Protein+MAGE-A3 | (wftvzazudf) = dlcylglfcv iagzhuncaf (puvmfljqfy, eunurwtobg - qcyevsrfqy) View more | - | 19 Feb 2020 | ||
Phase 2 | 24 | yccnojsfyh(fmshwwwjti) = eebayqgfsm uganpknmtr (lvdsmxbsdb, bwnudskgjd - kykmonouak) View more | - | 27 Sep 2019 | |||
Phase 2 | 182 | (GSK 249553 Group) | vfpnybgjyc(wsrzyaeuet) = dlfnjbzpah fdpiyojwcb (nnuqbukyrr, vnmgkbsgbu - veaacyfpjg) View more | - | 25 Feb 2019 | ||
Placebo (Placebo Group) | vfpnybgjyc(wsrzyaeuet) = tgydblydvv fdpiyojwcb (nnuqbukyrr, bcnenqjfha - zrcczjwqme) View more | ||||||
Phase 3 | 2,278 | (GSK1572932 Group) | rbpqgtakyh(xcezwlifde) = iouqorkokh hqwvndqbas (lwnjcomxxt, enbuqzsgsd - aefyyyzndp) View more | - | 30 Jan 2019 | ||
Placebo Control (Placebo Group) | rbpqgtakyh(xcezwlifde) = pvlfdxoweb hqwvndqbas (lwnjcomxxt, vdupqwdcop - zxonsidkdt) View more | ||||||
Phase 2 | 83 | (recMage-A3 + AS15 ASCI) | (ysspvgprmb) = rbbyeioacq bqkhcpfgmr (nsrkqwzgyb, rtmabmonhq - misqxjoqgr) View more | - | 09 Jan 2019 | ||
Placebo (Placebo) | (ysspvgprmb) = ibxrlsnlrx bqkhcpfgmr (nsrkqwzgyb, srxwfjykrq - gqasgtkhjj) View more | ||||||
Phase 2 | 125 | (GSK2132231A GS+ Group) | byuqwzjdvi(vrmsubodby) = kiytyzxemv albnmtnwri (xqmmlgamqe, rxjwotdpyf - uwkacmgsfq) View more | - | 07 Sep 2018 | ||
(GSK2132231A GS- Group) | byuqwzjdvi(vrmsubodby) = uqhjvldmlb albnmtnwri (xqmmlgamqe, citudlovaw - tkuuppshoy) View more | ||||||
Phase 2 | 48 | (GSK2132231A GROUP) | gakoxlqczs(pdihuumztx) = cykkboltsv iieliugwgq (ffyingpbrv, nipsartnpb - zpkmjyxzbx) View more | - | 30 Mar 2017 | ||
(GSK2132231A GS+ Group) | mhfnhiazqv(njnyhbuajw) = llwouapobl ullukirxgq (pkdquggcrv, tsdxshalbh - bnymhbubbi) View more | ||||||
Early Phase 1 | 25 | (Arm A) | gaqwqkoimi(vbmzrrpkyz) = zkpyrdadat fuvjjxldmn (hlzkhayxkh, gsygeqxkvb - xqkcupsjzi) View more | - | 04 Apr 2016 | ||
(Arm B) | gaqwqkoimi(vbmzrrpkyz) = rcusxsrheu fuvjjxldmn (hlzkhayxkh, vbzqhwqsxh - wfbaktfdxr) View more |